Using of Collagen Matrix for Maxillary Tuberosity Donor Area Preservation
NCT ID: NCT06039839
Last Updated: 2023-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2023-01-17
2025-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Analysis Using the Collagen Matrix and Autogenous Graft: Clinical Course, Aesthetic Results
NCT05870774
Clinical and Histological Outcomes of Using Collagen Matrix or Soft Tissue Graft Around Implants
NCT05123898
Increasing the Thickness of Soft Tissues in the Esthetic Zone Around Implants
NCT05551962
Impact of Soft Tissue Grafts on Tissue Alterations After Immediate Tooth Replacement
NCT02922075
Comparison of Free Gingival Graft and Linear Incision for Connective Tissue
NCT06365983
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The object of the study will be patients with an inclusion defect on the maxilla or mandible within 1-2 teeth combined with a soft tissue thickness deficiency in the area of dental implants (\< 2 mm) which requires mucosal augmentation operation. All patients will be randomly divided into two groups depending on the surgical procedure. In 1 group (n=15) the donor area will heal by secondary tension, and in 2 group (n=15) the collagen matrix "FibroMATRIX" will be used to close the wound defect in the donor area. The groups will be comparable in terms of gender and age characteristics. The randomisation of patients will be performed at the stage of surgical intervention as follows: after taking a free connective tissue graft and adapting the CTG to the recipient bed, an envelope with a randomly assigned method of donor area closure will be opened.
Patients in both groups will undergo dental implantation according to the standard protocol and healing abutment installation. In both groups of patients, a free connective tissue graft will be taken from the maxillary tuberosity and the autograft will be fixed to the vestibular full-thickness muco-periosteal flap with horizontal U-shaped sutures, followed by wound closure using simple interrupted sutures without tension.
Further, the collagen matrix "FibroMATRIX" (LLC "Cardioplant", Russia; registration in Russia 20/05/2019 No FSZ 2019/83671) will be adapted to the donor area for the patients of the 2 group, the patients of both groups will have to perform suturing of the wound surface using simple interrupted sutures.
In the postoperative period, standard antibacterial and anti-inflammatory therapy should be administered in combination with the use of topical antiseptics for daily care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
first group
Healing of the donor area will be accomplished without the use of collagen matrix
Closure of the donor area after CTG harvesting without the use of collagen matrix
1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant
2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area
3. Suturing of the wound in the donor site.
second group
Closure of the wound defect in the donor area in the region of the maxillary tuberosity will be carried out after CTG harvesting with the use of collagen matrix
Closure of the donor area after CTG harvesting with collagen matrix
1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant
2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area
3. Adaptation of sterile collagen matrix to the donor site
4. Suturing of the wound in the donor site
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Closure of the donor area after CTG harvesting without the use of collagen matrix
1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant
2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area
3. Suturing of the wound in the donor site.
Closure of the donor area after CTG harvesting with collagen matrix
1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation, placement of the dental implant
2. Harvesting of free connective tissue graft from the maxilla tuberosity area and it's fixation to the vestibular mucosal-periosteal flap, tight suturing of the wound in the recipient area
3. Adaptation of sterile collagen matrix to the donor site
4. Suturing of the wound in the donor site
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 18 and 45 years;
3. Included defects on the maxilla or mandible within 1-2 teeth combined with soft tissue thickness deficiency in the area of dental implants (\< 2 mm);
4. Teeth without periodontal pathology, probing depth should not exceed 3 mm across the entire dentoalveolar sulcus;
5. Satisfactory level of oral hygiene;
6. Absence of general diseases in the stage of exacerbation or decompensation
1. Patients who had previous harvesting of CTG from the same donor area;
2. Patients with impacted third molars in the donor area;
3. Presence of concomitant diseases in the stage of exacerbation or decompensation;
4. Patients with oncological diseases, as well as patients who have received radiotherapy and chemotherapy in the last 5 years;
5. Patients with a history of smoking for more than 10 years.
Exclusion Criteria
2. Pregnant and breastfeeding women;
3. Patients with blood coagulation disorders (haemophilia, Willebrand's disease, intake of anticoagulants);
4. Patients with diseases that impair soft tissue healing (insulin-dependent diabetes mellitus).
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
I.M. Sechenov First Moscow State Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Igor Ashurko
Role: PRINCIPAL_INVESTIGATOR
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Igor Ashurko
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.